Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Why Is CRISM Therapeutics One of Today’s Most-Watched UK Biotech Stocks?

CRISM Therapeutics Corporation has attracted renewed attention on18 August 2026, withLSE:CRTX rising 6.98%.

Ankur Sharma | 18 August 2026

Proteome Sciences Stock Rallies 11.42%: Could New Clinical Contracts Accelerate Growth?

Proteome Sciences plc has emerged as one of the notable UK healthcare movers on18 August 2026, withLSE:PRM gaining 11.42%.

Ankur Sharma | 18 August 2026

Cambridge Cognition Falls 6.1% — Is the Market Losing Confidence in the Recovery?

Cambridge Cognition spent the summer of 2026 telling a turnaround story: double-digit revenue growth, a debt-freeBalance Sheetand a push into consumer brain health. Yet the shares have drifted lower again, a reminder that on AIM a good narrative and a fragile micro-cap valuation can …

Ankur Sharma | 18 August 2026

Ondine Biomedical Drops 5.5% — Is the Healthcare Growth Story Losing Momentum?

Shares in the light-activated infection specialist have slipped again as investors count down to a make-or-break Phase 3 readout — with a thinning cash runway and no fresh catalyst to steady nerves. For a stock that has swung between 7.5p and 18.5p over the …

Ankur Sharma | 18 August 2026

SkinBioTherapeutics Slides 5.3% — Has the Market’s Skin-Health Enthusiasm Cooled?

A microbiome pioneer that once traded above 22p is now nursing a share price in single digits, a former chief executive accused of fabricating revenue, and a set of half-year accounts that had to be restated. For a company built on the science of …

Ankur Sharma | 18 August 2026

Fusion Antibodies Falls 4.8% — Is the Growth Story Running Out of Support?

Fusion Antibodies, the Belfast-based antibody engineering specialist, has spent 2026 stitching together contract wins, patent grants and a proprietary discovery platform it hopes will reshape its economics. Yet the shares slipped again in mid-August, a reminder that on AIM a thin,Illiquidmicro-cap can drift lower …

Ankur Sharma | 18 August 2026

MedPal AI Drops 3.3% — Is the AI Hype Cooling for This Tiny Stock?

MedPal AI has been one of London’s more eye-catching micro-cap stories of 2026, building a digital-health and pharmacyBusinessfrom a standing start into an £8.6m annualised revenue run rate in barely nine months. A modest dip of around 3.3% in a single session has prompted …

Ankur Sharma | 18 August 2026

Optima Health Slides 3.8% — Is Investor Enthusiasm Starting to Cool?

Optima Health has been one of the AIM market’s more talked-about small-caps this year, transformed by a £100m acquisition that made it Britain’s clear leader in occupational health. With full-year results due within days, a modest slide in the shares raises a fair question: …

Ankur Sharma | 18 August 2026

hVIVO Falls 3.8% — Is the Market Questioning the Next Growth Phase?

After a bruising 2025 that stripped hVIVO of its record margins, the market wants proof that the recovery is real. A first-half update showing lower revenue but a doubled order book has left investors torn between a promising 2026-2028 pipeline and the near-term reality …

Ankur Sharma | 18 August 2026

OptiBiotix Health Drops 2.6% — Is the Market Losing Its Appetite for the Health Story?

OptiBiotix has spent a decade promising that microbes can reshape how the world manages weight, cholesterol and gut health. With the shares slipping again in a quiet mid-August market, investors are asking whether the commercial turnaround finally taking shape is enough to rekindle a …

Ankur Sharma | 18 August 2026
Support

Hi! How can we help you today?

Loading…